Friday, Mar 21 2025 | Time 13:03 Hrs(IST)
Business EconomyPosted at: Mar 20 2025 6:42PM


Bharat Biotech forays into Cell & Gene Therapy

Hyderabad, Mar 20 (UNI) Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, on Thursday announced its foray into Cell & Gene Therapy (CGT).
In a release, the Hyderabad based vaccine maker also informed that it's Viral Vector Production at Genome Valley - expanding its expertise from vaccine innovation to leading-edge regenerative and personalised therapies that promise hope for millions.
This ushers in a new era of gene and cell therapies to tackle scientific challenges—such as targeted gene expression, immune system modulation, and long-term cell survival— The work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like hemophilia.
The 50,000-square-foot dedicated state-of-the-art CGT facility represents the next milestone in BBIL’s long-standing mission to deliver targeted, life-saving treatments that address unmet clinical needs globally by concentrating on critical conditions such as hematological malignancies and inherited blood disorders.
Outlining the purpose behind establishing India’s only vertically integrated cell and gene therapy facility, Dr. Krishna Ella, Executive Chairman, Bharat Biotech said, “Gene and cell therapies represent some of the most intricate, scientifically advanced treatments available today, involving sophisticated processes that require expertise in precise genetic manipulation and specialized manufacturing capabilities.
Bharat Biotech, with its extensive experience and proven excellence in viral vaccine manufacturing is uniquely positioned to master these complexities and produce human-grade vectors at the scale and consistency needed for clinical trials, thus advancing the global fight against rare and complex diseases.”
Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said “Bharat aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily in developed nations or premium institutions. Our established expertise in producing viral vectors are essential for cell and gene therapy applications - the crucial material for anti-cancer and genetic disorders and robust clinical development abilities for QC release".
Additionally, it has capabilities to manufacture multiple platform products for various disease indications, including blood cancers, solid organ cancers, and genetic disorders, Dr. Raches added.
Prof. Krishanu Saha, University of Wisconsin, Madison, said,“My lab has initiated a pioneering collaboration with Bharat Biotech to develop next-generation CAR (chimeric antigen receptor) cell therapies using AI. Ultimately, genuine innovations in both product design and scaling will enhance patient care globally.”

“Cell & Gene Therapy aligns with BBIL’s broader vision of expanding beyond traditional vaccines into personalized medicine. Leveraging our proven expertise in forging strategic global partnerships, this initiative will enable the rapid translation of advanced scientific discoveries—from potent therapeutic vectors to in vivo CAR (chimeric antigen receptor) generation—into real-world solutions.” Dr. Krishna Ella added.
UNI KNR CS
Tags: #Bharat Biotech forays into Cell & Gene Therapy
More News
Sensex rises over 100 pts

Sensex rises over 100 pts

21 Mar 2025 | 11:00 AM

Mumbai, Mar 21 (UNI) The BSE Sensex remained strong for the fifth session on Friday, rising 174.52 pts at 76,522.58 in opening session as buying was seen across the board.

see more..

Bandhan Bank collaborates with Salesforce to drive digital transformation

20 Mar 2025 | 7:29 PM

Kolkata, Mar 20 (UNI) Salesforce on Thursday announced its partnership with Bandhan Bank to revolutionize its loan origination systems (LOS) and deliver a seamless, digital-first experience for customers.

see more..

AP: Adani Gangavaram Port inducts multi-purpose fire tender

20 Mar 2025 | 7:01 PM

Visakhapatnam, Mar 20 (UNI) Adani Gangavaram Port announced on Thursday that it has reinforced its safety infrastructure with the induction of a state-of-the-art multi-purpose fire tender.

see more..

Bharat Biotech forays into Cell & Gene Therapy

20 Mar 2025 | 6:42 PM

Hyderabad, Mar 20 (UNI) Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, on Thursday announced its foray into Cell & Gene Therapy (CGT).

see more..
Rupee rises 5 paise against USD

Rupee rises 5 paise against USD

20 Mar 2025 | 6:17 PM

Mumbai, Mar 20 (UNI) The Rupee on Thursday gained 5 paise to close at 86.37 against the US Dollar on brisk selling of USD by bankers and importers, dealers at the Forex Market said.

see more..